伊甸表示，長照、養護機構裡的服務使用者，大多數為年長者、重度的身心障礙朋友，因身心受到限制，即便今天出現了症狀，也無法隨時就醫採檢，再加上第一線的照顧人員除了面臨人力不足、龐大照顧壓力外，每天還要面對染疫的風險，在這樣的情況下，更是需要社會大眾及企業的愛心支持。因此，非常感謝基龍米克斯生物科技股份有限公司的熱心公益，除了提升伊甸防疫量能，幫助第一線人員降低染疫風險外，也讓照顧服務可以安心且持續的進行。
Genomics Teams Up with NTU Biotech Center to Establish a Forward-Looking Technology Industry-Academia Collaboration and Education Platform for Win-Win Cooperation
Genomics Bioscience & Technology Co. Ltd., a leading domestic company in genetic sequencing (referred to as “Genomics”, stock code: 4195), signed a “Memorandum of Understanding for Forward-Looking Technology Industry-Academia Collaboration and Education Platform” with NTU Biotechnology Center (referred to as “NTU Biotech Center”) today (14th). Both parties will jointly establish a core laboratory and create a forward-looking biotechnology practical field within the NTU campus. They will also organize a series of applied courses, allowing students to embrace the latest biotechnology techniques, align with industry development trends, and foster outstanding local biotechnology talents through industry-academia collaboration. This initiative aims to strengthen Taiwan's innovative research and development capabilities in biotechnology, enhancing the competitiveness and status of Taiwan's biotechnology industry in the international market.
APR.14
2022
2022
Genomics Reports Last Year's EPS of NT$0.32, Plans NT$0.2 Stock Dividend
Genomics Bioscience & Technology Co. Ltd., (referred to as “Genomics”, stock code: 4195), the leading domestic gene sequencing company, announced today (30th) that its Board has approved the 2021 financial report. The consolidated revenue for 2021 was NT$389,965 thousand, a 12% decrease from the previous year. The net profit attributable to the parent company was NT$18,738 thousand, a 2927% increase year-over-year, resulting in an after-tax earnings per share (EPS) of NT$0.32.
MAR.30
2022
2022
